#ASH17: Spark triggers a backlash as early hemophilia A gene therapy data looks shaky
Following up on its impressive work on a new gene therapy for hemophilia B, Spark Therapeutics $ONCE has offered a peek at its cards on the early data from a separate program it has on hemophilia A. And it’s clear that there’s a lot of work to be done.
Looking over a tiny group of patients with varying degrees of exposure to the factor VIII gene carrying SPK-8011, investigators tracked a range of responses ranging from single to double-digit responses in factor VIII levels. And coming after some solid data from BioMarin, which has the leading gene therapy program in hemophilia A, investors quickly clipped 33% off of Spark’s share price this morning at the unsteady results it produced.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.